Research map: De-escalation of inhaled corticosteroids and other maintenance asthma therapies in dupilumab-treated patients with severe asthma: a real-world study

Back to the article

Papers in this map

  1. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma · Kian Fan Chung · 2013 · 3994 citations · Cited by this paper
  2. Immunosuppressive medication patterns in rheumatoid arthritis–associated interstitial lung disease by antifibrotic documentation status: A multicenter U.S. electronic health record study · 2026 · Related
  3. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma · Mario Castro · 2018 · 2002 citations · Cited by this paper
  4. Neuromuscular junction biomarker CAF22 predicts functional decline in patients with chronic obstructive pulmonary disease · 2026 · Related
  5. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma · Klaus Friedrich Rabe · 2018 · 1195 citations · Cited by this paper
  6. Adults with congenital lung malformations: A descriptive analysis of an underexplored population · 2026 · Related
  7. Mechanisms of Dupilumab · Hani Harb · 2019 · 507 citations · Cited by this paper
  8. Use of dual targeting during volume control ventilation is associated with increased delivery of non-lung-protective tidal volumes · 2026 · Related
  9. An expert consensus framework for asthma remission as a treatment goal · Andrew N Menzies-Gow · 2019 · 439 citations · Cited by this paper
  10. Step-DAWN: an Italian algorithm proposed for the management of inhaled corticosteroids in severe asthma · 2026 · Related
  11. Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma · Enrico Marco Heffler · 2018 · 238 citations · Cited by this paper
  12. Phenotypic patterns and outcomes of connective tissue disease-associated pulmonary arterial hypertension: a Saudi single center experience · 2026 · Related
  13. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study · David J. Jackson · 2023 · 155 citations · Cited by this paper
  14. Sex-based differences in long-term respiratory and pulmonary vascular outcomes after acute pulmonary embolism: A propensity-matched analysis of 795,338 patients · 2026 · Related
  15. Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies · Susanne Hansen · 2023 · 152 citations · Cited by this paper
  16. Rheumatoid arthritis-associated interstitial lung disease: Pathogenesis, risk stratification, and management · 2026 · Related
  17. Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial · Liam Gabriel Heaney · 2020 · 146 citations · Cited by this paper
  18. Oxidative Stress–Driven Dysregulation of the MMP-2/TIMP-2 Axis in Chronic Obstructive Pulmonary Disease: Molecular Mechanisms, Genetic Polymorphisms, and Therapeutic Implications · 2026 · Related
  19. Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment · Michael S. Blaiss · 2023 · 134 citations · Cited by this paper
  20. Smoking cessation and depression risk in newly diagnosed COPD patients: A nationwide cohort study · 2026 · Related
  21. Oral corticosteroid use, morbidity and mortality in asthma: A nationwide prospective cohort study in Sweden · Magnus Per Ekström · 2019 · 95 citations · Cited by this paper
  22. Adherence to inhaled corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma · G d’Ancona · 2020 · 89 citations · Cited by this paper
  23. Type 2 inflammation and biological therapies in asthma: Targeted medicine taking flight · Imran Howell · 2023 · 89 citations · Cited by this paper
  24. The dose–response characteristics of inhaled corticosteroids when used to treat asthma: An overview of Cochrane systematic reviews · Neville Adams · 2006 · 75 citations · Cited by this paper
  25. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma · Arnaud Bourdin · 2019 · 45 citations · Cited by this paper
  26. Adherence to Asthma Biologics · Jacob T. Maddux · 2020 · 41 citations · Cited by this paper
  27. Use of High-Dose Inhaled Corticosteroids and Risk of Corticosteroid-Related Adverse Events in Asthma Findings From the NORDSTAR Cohort · Anna von Bülow · 2025 · 40 citations · Cited by this paper
  28. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry · Wenjia Chen · 2023 · 39 citations · Cited by this paper
  29. Adrenal suppression from exogenous glucocorticoids: Recognizing risk factors and preventing morbidity · Alexandra H. Ahmet · 2021 · 23 citations · Cited by this paper
  30. Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics · Marco Caminati · 2020 · 20 citations · Cited by this paper
  31. ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up · Laura Pini · 2025 · 11 citations · Cited by this paper
  32. Oral Corticosteroid Use in Asthma: A Wolf in Sheep's Clothing · Anne L. Fuhlbrigge · 2021 · 8 citations · Cited by this paper
  33. Benralizumab: Effectiveness in Patients with Uncontrolled Severe Eosinophilic Asthma at 6 and 12 Months at a Third-Level Care Hospital. Capacity for ICS-LABA Therapy Reduction · Yair González-Tuyub · 2024 · 5 citations · Cited by this paper

Source: OpenAlex (CC0)